ReShape Lifesciences Inc.
RSLS
$3.11
$0.8235.81%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 68.28% | 37.38% | 72.98% | 74.09% | 73.21% |
| Total Depreciation and Amortization | -82.14% | -85.71% | -96.37% | -94.03% | -93.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -766.88% | 118.39% | -101.03% | -96.76% | -97.44% |
| Change in Net Operating Assets | 157.53% | 157.76% | 140.56% | 91.74% | -384.27% |
| Cash from Operations | 67.98% | 73.90% | 64.25% | 56.29% | 28.66% |
| Capital Expenditure | -- | -- | 100.00% | 100.00% | 72.52% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -100.00% | 10.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 100.00% | 100.00% | 97.03% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -35.14% | -99.86% | -60.68% | -60.69% | -44.69% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 200.00% | -- | -- |
| Cash from Financing | -37.28% | -96.15% | -56.98% | -60.69% | -44.69% |
| Foreign Exchange rate Adjustments | -366.67% | -- | 123.08% | 122.73% | 86.36% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 102.06% | -723.51% | 84.97% | 48.90% | -3.56% |